# Cyrus Biotechnology

Cyrus Biotechnology is an Asset Manager based in Seattle, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Seattle, United States
- **Region:** North America
- **Address:** Seattle, WA, United States
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** cyrusbio.com
- **LinkedIn:** https://www.linkedin.com/company/cyrus-biotechnology

## Regulatory record

- **Reports private funds:** No

## About

Cyrus Biotechnology was founded in 2016 by Lucas Nivon, who previously worked with David Baker at the University of Washington's Institute for Protein Design. The company licenses and commercializes the Rosetta software suite, a molecular modeling platform used for designing novel proteins. Wealth origin is not publicly disclosed; the firm is structured as a private technology company, not a family office. The firm's core offering combines the Rosetta software with custom cloud computing and machine learning tools to accelerate protein engineering. Clients include pharmaceutical companies, agricultural biotechs, and industrial enzyme producers. Cyrus has disclosed partnerships with entities like Merck and Ginkgo Bioworks, though specific financial terms are not public. Geographically, the firm focuses on North America and Europe, with some engagement in Asia. Cyrus has raised venture capital, including a $8M Series A in 2019 led by F-Prime Capital and a $5.7M round from the Washington Research Foundation. It is headquartered in Seattle, Washington, with no publicly listed additional offices. The company has not disclosed its team size. An operational milestone from the last 24 months: October 2024: Cyrus expanded its protein design services to include generative AI models trained on high-throughput experimental data. Cyrus's structural differentiator is its exclusive commercial license to the Rosetta software suite, a tool that is also used extensively in academic research. This IP position gives it a unique moat in computational protein design, while its services model reduces the capital intensity and risk profile compared to therapeutic-development peers.

## Sectors

- AI/ML
- Enterprise Software
- Digital Health
- Biotechnology
- Industrial Tech

## People

- Lucas Nivon — CEO
- David Baker — Scientific Founder

## Questions

### Who runs investment decisions at Cyrus?

Cyrus is led by CEO Lucas Nivon, who founded the company in 2016. The board includes representatives from venture investors. There is no single-family-office structure; capital allocation is determined by the executive team and board based on client contracts and development milestones.

### Which investment stages does Cyrus typically target?

Cyrus does not invest external capital. It is a product and services company that targets partnerships with both early-stage biotechs and established pharmaceutical firms. Its clients span preclinical to commercial stages.

### What sectors does Cyrus explicitly avoid?

Cyrus does not publicly disclose any explicit sector avoidance. Its technology is applicable across protein-engineering domains, but it has no disclosed focus on gene editing or small-molecule drug development.

## Related profiles

- [Raises.com Inc.](https://altss.com/profile/raisescom-inc)
- [PIK Investments LLC](https://altss.com/profile/pik-investments-llc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cyrus-biotechnology-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology